Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
65
UTHR Quote, Financials, Valuation and Earnings
Last price:
$484.21
Seasonality move
:
8.74%
Day range:
$470.13 - $482.67
52-week range:
$266.98 - $492.62
Dividend yield:
0%
P/E ratio:
18.23x
P/S ratio:
7.41x
P/B ratio:
3.14x
Volume:
301.5K
Avg. volume:
510.3K
1-year change:
30.42%
Market cap:
$20.7B
Revenue:
$2.9B
EPS (TTM):
$26.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$812.9M | $7.31 | 11.26% | 17.13% | $518.25 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 64.56% | -3.9% | $220.41 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$130.5M | -$1.05 | -32.79% | -81.88% | $85.47 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 30.84% | 53.75% | $1,045.59 |
|
LQDA
Liquidia Corp.
|
$19.5M | -$0.35 | 2761.17% | -50.89% | $39.00 |
|
MNKD
MannKind Corp.
|
$80.2M | $0.03 | 31.5% | 17.65% | $9.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$480.96 | $518.25 | $20.7B | 18.23x | $0.00 | 0% | 7.41x |
|
INSM
Insmed, Inc.
|
$206.78 | $220.41 | $44.1B | -- | $0.00 | 0% | 88.00x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$81.84 | $85.47 | $13.3B | -- | $0.00 | 0% | 13.93x |
|
LLY
Eli Lilly & Co.
|
$1,033.56 | $1,045.59 | $925.1B | 51.12x | $1.50 | 0.58% | 15.86x |
|
LQDA
Liquidia Corp.
|
$33.74 | $39.00 | $2.9B | -- | $0.00 | 0% | 41.65x |
|
MNKD
MannKind Corp.
|
$5.59 | $9.39 | $1.7B | 59.34x | $0.00 | 0% | 5.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
-- | 1.213 | -- | 5.61x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.444 | 19.43% | 2.51x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
LQDA
Liquidia Corp.
|
90.03% | 0.315 | 10.09% | 1.88x |
|
MNKD
MannKind Corp.
|
124.56% | 0.023 | 13.7% | 2.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp.
|
$698.6M | $389.3M | 18.69% | 19.2% | 48.69% | $346.1M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
LQDA
Liquidia Corp.
|
$50.9M | $1.8M | -79.94% | -221.75% | 3.25% | -$10.7M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
United Therapeutics Corp. vs. Competitors
-
Which has Higher Returns UTHR or INSM?
Insmed, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of -259.95%. United Therapeutics Corp.'s return on equity of 19.2% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About UTHR or INSM?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 7.75%. On the other hand Insmed, Inc. has an analysts' consensus of $220.41 which suggests that it could grow by 6.59%. Given that United Therapeutics Corp. has higher upside potential than Insmed, Inc., analysts believe United Therapeutics Corp. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.7 5 0 INSMInsmed, Inc.16 1 0 -
Is UTHR or INSM More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock UTHR or INSM?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or INSM?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. United Therapeutics Corp.'s net income of $338.7M is higher than Insmed, Inc.'s net income of -$370M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 18.23x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.41x versus 88.00x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.41x 18.23x $799.5M $338.7M INSMInsmed, Inc.88.00x -- $142.3M -$370M
-
Which has Higher Returns UTHR or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of -82.06%. United Therapeutics Corp.'s return on equity of 19.2% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About UTHR or IONS?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 7.75%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.43%. Given that United Therapeutics Corp. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe United Therapeutics Corp. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.7 5 0 IONSIonis Pharmaceuticals, Inc.11 6 0 -
Is UTHR or IONS More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.
-
Which is a Better Dividend Stock UTHR or IONS?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or IONS?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. United Therapeutics Corp.'s net income of $338.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 18.23x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.41x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.41x 18.23x $799.5M $338.7M IONSIonis Pharmaceuticals, Inc.13.93x -- $156.7M -$128.6M
-
Which has Higher Returns UTHR or LLY?
Eli Lilly & Co. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 31.72%. United Therapeutics Corp.'s return on equity of 19.2% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About UTHR or LLY?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 7.75%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that United Therapeutics Corp. has higher upside potential than Eli Lilly & Co., analysts believe United Therapeutics Corp. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.7 5 0 LLYEli Lilly & Co.17 8 0 -
Is UTHR or LLY More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock UTHR or LLY?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTHR or LLY?
United Therapeutics Corp. quarterly revenues are $799.5M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. United Therapeutics Corp.'s net income of $338.7M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 18.23x while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.41x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.41x 18.23x $799.5M $338.7M LLYEli Lilly & Co.15.86x 51.12x $17.6B $5.6B
-
Which has Higher Returns UTHR or LQDA?
Liquidia Corp. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of -6.5%. United Therapeutics Corp.'s return on equity of 19.2% beat Liquidia Corp.'s return on equity of -221.75%.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B LQDALiquidia Corp.93.65% -$0.04 $221.2M -
What do Analysts Say About UTHR or LQDA?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 7.75%. On the other hand Liquidia Corp. has an analysts' consensus of $39.00 which suggests that it could grow by 30.41%. Given that Liquidia Corp. has higher upside potential than United Therapeutics Corp., analysts believe Liquidia Corp. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.7 5 0 LQDALiquidia Corp.6 0 1 -
Is UTHR or LQDA More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.777%.
-
Which is a Better Dividend Stock UTHR or LQDA?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or LQDA?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than Liquidia Corp. quarterly revenues of $54.3M. United Therapeutics Corp.'s net income of $338.7M is higher than Liquidia Corp.'s net income of -$3.5M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 18.23x while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.41x versus 41.65x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.41x 18.23x $799.5M $338.7M LQDALiquidia Corp.41.65x -- $54.3M -$3.5M
-
Which has Higher Returns UTHR or MNKD?
MannKind Corp. has a net margin of 42.36% compared to United Therapeutics Corp.'s net margin of 9.72%. United Therapeutics Corp.'s return on equity of 19.2% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About UTHR or MNKD?
United Therapeutics Corp. has a consensus price target of $518.25, signalling upside risk potential of 7.75%. On the other hand MannKind Corp. has an analysts' consensus of $9.39 which suggests that it could grow by 67.96%. Given that MannKind Corp. has higher upside potential than United Therapeutics Corp., analysts believe MannKind Corp. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings UTHRUnited Therapeutics Corp.7 5 0 MNKDMannKind Corp.8 0 0 -
Is UTHR or MNKD More Risky?
United Therapeutics Corp. has a beta of 0.861, which suggesting that the stock is 13.874% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.928%.
-
Which is a Better Dividend Stock UTHR or MNKD?
United Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics Corp. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios UTHR or MNKD?
United Therapeutics Corp. quarterly revenues are $799.5M, which are larger than MannKind Corp. quarterly revenues of $82.1M. United Therapeutics Corp.'s net income of $338.7M is higher than MannKind Corp.'s net income of $8M. Notably, United Therapeutics Corp.'s price-to-earnings ratio is 18.23x while MannKind Corp.'s PE ratio is 59.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics Corp. is 7.41x versus 5.50x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTHRUnited Therapeutics Corp.7.41x 18.23x $799.5M $338.7M MNKDMannKind Corp.5.50x 59.34x $82.1M $8M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
